Triple Monoamine Reuptake Inhibitor

Tesofensine

NS2330 • Oral Small-Molecule Appetite Regulator

Tesofensine is an orally active small molecule—not a peptide—that inhibits serotonin, norepinephrine, and dopamine reuptake to reduce appetite, food reward, and body weight while modestly increasing energy expenditure.

Weight Loss Appetite Control Food Reward Oral

Protocol Snapshot

Tesofensine Quick Reference

Verified Vendors

Tesofensine

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Starting Dose

0.25mg

Once daily in the morning.

Target Dose

0.5mg

Once daily after initial tolerance.

Class

Triple Reuptake Inhibitor

Review the full protocol details below.

Route

Oral

Review the full protocol details below.

Peptide Grade

GradeC

Strong human weight-loss results and convenient oral dosing support its potential. Increased heart rate, stimulant-like cardiovascular and psychiatric effects, and limited long-term safety data substantially reduce its overall practicality.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is Tesofensine?

Tesofensine is not a peptide. It is an orally active small-molecule triple monoamine reuptake inhibitor that increases serotonin, norepinephrine, and dopamine signaling in the brain.

Originally developed under the code name NS2330 for neurodegenerative disease, tesofensine was redirected toward obesity treatment after clinical-trial participants consistently lost weight.

Its long half-life is approximately 234 hours, or about 10 days. The active M1 metabolite lasts even longer, so blood levels accumulate gradually and may take 6–8 weeks to reach steady state.

Different From GLP-1 Drugs

GLP-1 agonists produce hormonal satiety and slower gastric emptying. Tesofensine works centrally by reducing hunger, food reward, and compulsive food seeking while modestly increasing energy expenditure.

Tesofensine Benefits

Significant Weight Loss

In Phase 2, 0.5mg daily plus dietary intervention produced 11.2% mean total weight loss over 24 weeks, or 9.2 percentage points more than diet plus placebo.

Appetite Suppression

Reduces hunger and food seeking through serotonin, norepinephrine, dopamine, alpha-1 adrenergic, and D1-receptor pathways.

Reduced Food Reward

Dopamine-transporter inhibition may reduce the compulsive reward value of food and quiet persistent food noise.

Fat Oxidation

A controlled study reported increased 24-hour fat oxidation and higher nighttime energy expenditure.

Body-Fat Reduction

Trials reported dose-dependent reductions in body fat and waist circumference with relative preservation of lean mass.

Oral Administration

Greater than 90% oral bioavailability and once-daily dosing provide a practical alternative to injections.

Protocol Planning

Dosing, cycling, and preparation

Tesofensine Dosing Protocol

Tesofensine has an extremely long half-life and accumulates over weeks. Dose changes should be slow, and higher doses produce diminishing returns with more cardiovascular and psychiatric effects.

Standard Protocol

Weeks 1–2

0.25mg once daily

Week 3+

0.5mg once daily

Timing

Morning

Food

With or without food

Bioavailability

Greater than 90%

Peak Level

Approximately 5–8 hours after dosing

Duration

Clinical trials used 24 weeks

Studied Dose Range

0.25mg

6.5% mean total weight loss; 4.5 percentage points above placebo

0.5mg

11.2% mean total weight loss; 9.2 percentage points above placebo

1mg

12.6% mean total weight loss; 10.6 percentage points above placebo, with more adverse effects

Maximum

Do not exceed 0.5mg without medical supervision

Steady State Takes Time

Because the half-life is about 10 days, full steady-state exposure takes roughly 6–8 weeks. Side effects may also build gradually rather than appearing immediately.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users commonly report 8–15 pounds of weight loss during the first 4–8 weeks.
Reduced food noise and cravings are more consistent than physical stomach fullness.
Many users report better alertness, focus, and mild mood elevation early in treatment.
Some prefer tesofensine to GLP-1 drugs because digestion remains more normal.
Morning dosing often improves sleep tolerance.
Users switching from GLP-1 drugs sometimes report better training energy.

Negative Reports

Dry mouth is nearly universal and constipation is common.
Resting heart rate often increases by 5–10 beats per minute.
Anxiety, irritability, insomnia, or low mood occur more often at higher doses.

Stacking & Synergy

Potential Tesofensine pairings and tracking context

Tesofensine Stacking & Synergy

Tesofensine + GLP-1 Agonists

Different mechanisms may produce strong combined appetite suppression, but severe undereating and protein deficiency are major concerns.

Tesofensine + 5-Amino-1MQ

Different central and cellular mechanisms with no established direct interaction, though controlled combination data is absent.

Antidepressants

Do not combine with SSRIs, SNRIs, MAOIs, bupropion, or serotonergic drugs because of interaction and serotonin-syndrome risk.

Stimulants

Avoid amphetamine, methylphenidate, modafinil, and other stimulants because cardiovascular and psychiatric effects may compound.

Free with login

Track in Journal

Because tesofensine accumulates slowly, weekly trend tracking is more useful than isolated daily observations.

Dose, timing, and days at the current dose.
Weight trend, appetite suppression, food noise, and daily protein intake.
Resting heart rate, blood pressure, palpitations, and training tolerance.
Sleep quality, anxiety, irritability, mood, dry mouth, and constipation.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

Tesofensine Side Effects

The principal concerns are dry mouth, insomnia, increased heart rate, constipation, and neuropsychiatric effects.

Tesofensine has not completed a large cardiovascular-outcomes trial comparable to those required for many obesity medications. Long-term cardiovascular safety remains unresolved.

In Published Research

Common: dry mouth, insomnia, constipation, nausea, headache, and increased heart rate.
The 0.5mg dose increased heart rate by roughly 7 beats per minute in Phase 2.
Higher doses produced more depressed mood and psychiatric adverse events.

What Users Report

Dry mouth is the most persistent and nearly universal complaint.
Insomnia is common when taken after the morning.
Anxiety, irritability, low mood, palpitations, or severe appetite suppression require caution.

Tesofensine Contraindications and Precautions

Do Not Use If You Have

Current SSRI, SNRI, MAOI, bupropion, serotonergic, or stimulant medication use.
Uncontrolled hypertension, cardiovascular disease, stroke, arrhythmia, or significant tachycardia.
Major depressive disorder, bipolar disorder, psychosis, or active psychiatric illness.
Pregnancy or breastfeeding.

Use Caution With

Controlled hypertension, anxiety disorders, insomnia, baseline heart rate above 90, or liver disease.
Strong CYP3A4 inhibitors or inducers, including grapefruit, ketoconazole, ritonavir, rifampin, carbamazepine, and St. John's Wort.
GLP-1 agonists or other appetite suppressants because severe undereating may occur.

Drug Interactions

Do not combine with SSRIs, SNRIs, MAOIs, bupropion, stimulants, tramadol, or other serotonergic medications. CYP3A4 inhibitors can raise exposure, while CYP3A4 inducers can lower it.

Monitoring

Track resting heart rate, blood pressure, mood, anxiety, sleep, protein intake, hydration, bowel function, and signs of serotonin syndrome. Stop and seek care for chest pain, severe palpitations, suicidal thoughts, confusion, fever, or muscle twitching.

Regulatory Status

Tesofensine is not FDA approved in the United States. A Phase 3 program was completed in Mexico, but the Mexican marketing application remained under regulatory review after a revised dossier was resubmitted in February 2025.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Tesofensine has earned serious attention in our fat-loss circles because it is a triple reuptake inhibitor of dopamine, norepinephrine, and serotonin that suppresses appetite hard, may modestly increase energy expenditure, and can deliver steady weight loss without the gastric-slowing effects that define GLP-1 drugs.

From reports and our own n=1 runs, the standout effects are significant appetite suppression, better focus and motivation, and consistent fat loss. Some users describe it as smoother than classic stimulants, but increased heart rate, blood pressure, and psychiatric effects mean it should not be treated as non-stimulatory. It is an interesting theoretical pairing with Retatrutide for stubborn fat-loss phases, although controlled combination data is absent and the combined appetite suppression could make adequate calorie and protein intake difficult.

Biggest knocks: It is still relatively understudied long term in healthy users, with most published weight-loss data coming from older obesity trials. It is also not as set-and-forget as some peptides. Its roughly 10-day half-life means exposure and side effects can build over weeks, so dose changes take time to fully show themselves. Some users report tolerance, but no evidence-based tapering protocol has been established. For those reasons, we see Tesofensine as a potent but higher-maintenance fat-loss tool, not an automatic first choice.